A single dose of MM120 (lysergide D-tartrate) reduces anxiety in a dose-dependent way in adults with moderate to severe generalized anxiety disorder. In a phase 2b randomized, double-blind, placebo-controlled trial with 198 participants, the 100-µg and 200-µg doses produced significantly greater reductions in Hamilton Anxiety Rating Scale scores at 4 weeks than placebo, with differences of -5.0 and -6.0 points, respectively. Lower doses (25 µg and 50 µg) did not differ from placebo. Common side effects included visual perceptual changes and nausea, which increased with dose.
A proof-of-concept study tested the MindMed Session Monitoring System (MSMS), a continuous passive monitoring system designed for use during treatment sessions with consciousness-altering drugs. Participants completed 129 Spravato sessions with MSMS at an outpatient psychiatry clinic. Results indicated high rates of data quality and self-reported usability among both participants and healthcare providers. These findings suggest that such systems could assist with patient monitoring during consciousness-altering treatments, potentially reducing the burden on providers and improving accessibility.
Early integration of palliative care for patients with gynecologic cancers is beneficial, but disparities and barriers persist, leading to late hospice referrals and aggressive end-of-life care. Multidisciplinary efforts are increasing to promote earlier goals-of-care discussions. Beyond symptom burdens, financial toxicity causes harmful cost-mitigation choices. Psychedelic-assisted therapy shows promise for depression in advanced cancer patients. Continued research is needed to address symptomatic and psychosocial suffering globally.